On June 17, 2026 Defence Therapeutics Inc. ("Defence" or the "Company"), (CSE: DTC, OTCQB: DTCFF, FSE: DTC) a publicly traded biotechnology and precision intracellular drug-delivery company, reported its participation in the BIO International Convention 2026, taking place June 22–25 in San Diego, California.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Defence’s team will be available throughout the conference to meet with pharmaceutical and biotechnology companies, investors, and potential strategic collaborators interested in exploring partnership opportunities involving Defence’s proprietary Accum platform.
Accum is designed to enhance intracellular delivery by promoting endosomal escape and improving delivery to target cellular compartments. The platform is being applied across multiple therapeutic modalities, including antibody-drug conjugates (ADCs) and radiopharmaceutical drug conjugates (RDCs), where efficient intracellular delivery remains a critical challenge.
Defence is actively seeking partnerships with innovative pharmaceutical and biotechnology companies, biosimilar developers, and technology providers interested in leveraging Accum to unlock additional value from their therapeutic programs. Partnership opportunities include the development of novel Accum-enabled ADCs, enhancement of biosimilar products, revitalization of existing or discontinued assets, and co-development of advanced delivery and linker technologies. Accum can be incorporated into ADC programs without restarting the engineering process, enabling integration at any stage of development, from discovery through clinical evaluation.
"BIO International Convention is one of the most important gatherings for the global biotechnology industry, bringing together innovators, investors, and pharmaceutical leaders from around the world," said Sébastien Plouffe, Chief Executive Officer of Defence Therapeutics. "For Defence, it provides a unique opportunity to showcase the potential of our Accum platform and engage with organizations seeking innovative approaches to improve the delivery and effectiveness of advanced therapeutics. We look forward to meeting with potential partners and exploring opportunities to create value through collaborations."
Companies interested in scheduling a meeting with Defence during BIO 2026 are encouraged to contact the Company in advance through the BIO Partnering platform or by reaching out directly to the Defence team at [email protected].
(Press release, Defence Therapeutics, JUN 17, 2026, View Source;utm_medium=rss&utm_campaign=defence-therapeutics-to-participate-in-bio-international-convention-2026-next-week-for-strategic-partnership-discussions [SID1234668772])